HTG, Inc., provider of the qNPA system, a novel array-based gene expression assay technology and service partner for the life sciences industry, today announced that it has appointed Billie-Jo (BJ) Kerns as the vice president of strategic marketing and business development. Kerns is responsible for developing and implementing HTG’s strategic marketing plan and business development strategy including HTG’s entry into diagnostics.

“BJ is the perfect complement to our executive team and we are fortunate to have her on board,” said HTG President and CEO TJ Johnson. “She brings more than twenty seven years of marketing and business development experience along with a successful track record in diagnostics. BJ has the ideal set of skills and expertise to help HTG penetrate the clinical research market and develop its diagnostic applications utilizing our unique qNPA system for clinically relevant gene expression signatures.”

Prior to joining HTG Kerns was the director of integrated solutions and molecular diagnostics at Promega Corp. Inc. A seasoned diagnostics executive, Kerns held several positions at Ventana Medical Systems Inc., including director of women’s health, director of strategic marketing and senior director of product technical support in operations. While at Ventana she launched the company’s first FDA-cleared companion diagnostic PATHWAY® HER-2. Kerns has also managed a variety of functions at BioGenex and Becton Dickinson, including business development, sales and marketing, and research and development.

Kerns remarked: “It is an exciting time to join HTG. I look forward to working with TJ and the rest of the management team as we build on the success of the HTG platform to expand its diagnostic capabilities.”

Kerns received an AAS in Medical Technology from Elon College in Elon, North Carolina, and a BS in Health Care Management from Century University in Albuquerque, New Mexico. She has received a certification in Managing Strategic Resources from Darden Executive Education at the University of Virginia.

HTG’s qNPA technology is used to carry out quantitative multiplexed, gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development. HTG’s platform allows scientists to test any sample, including fixed tissues, while avoiding the need for extraction or target amplification. The platform provides high-quality quantitative test results enabling clients to compress drug discovery and development program timelines, increase program success and reduce costs.

About HTG

Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital. Additional information is available at

Schwartz Communications, Inc.
Andrea tenBroek/ Chris Stamm, 781-684-0770